AbbVie (ABBV) Reports Strong 3Q and Long term outlook; Cowen Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AbbVie Reports Third-Quarter 2015 Financial Results
October 30, 2015 6:55 AM EDTNORTH CHICAGO, Ill., Oct. 30, 2015 /PRNewswire/ --Â AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2015.
"We are pleased with our outperformance in the third quarter and our progress year-to-date. We've driven strong commercial, operational and R&D execution, resulting in industry-leading top- and bottom-line performance," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We are well-positioned to deliver robust EPS growth in 2015 and beyond, and we continue to make significant progress advancing our pipeline and other strategic actions that will help AbbVie achieve top-tier growth over the... More
AbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance
October 30, 2015 6:54 AM EDTNORTH CHICAGO, Ill., Oct. 30, 2015 /PRNewswire/ --Â AbbVie (NYSE: ABBV) today outlined the company's long-term strategic and financial objectives, including expectations for growth and other financial metrics over its long-range plan, through 2020.
"AbbVie is well-positioned to deliver strong top- and bottom-line performance through 2020 and beyond," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We have built a strong foundation, establishing growth platforms in some of the largest and most attractive market segments. And, we have a robust and compelling pipeline which will contribute significantly to our performance over our... More
IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent
October 28, 2015 8:30 AM EDTNORTH CHICAGO, Ill., Oct. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that IMBRUVICA® (ibrutinib) was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent. IMBRUVICA won this distinction out of 24 category nominees, all of which were deemed innovative in the field of medicine and were approved by the U.S. Food and Drug Administration (FDA) within the past five years. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
"We are honored that IMBRUVICA, a first-in-class,... More
